Carvolix

Carvolix is a pre-clinical stage biotechnology company focused on developing targeted small molecule inhibitors for the treatment of aggressive and metastatic solid tumors. The company's primary focus is on targeting Carbonic Anhydrase IX (CAIX), an enzyme that is highly overexpressed in hypoxic tumor environments and plays a critical role in pH regulation and cancer cell survival. By inhibiting CAIX, Carvolix aims to disrupt the tumor's ability to manage acid stress, thereby reducing tumor growth and preventing metastasis. Their lead programs are currently undergoing optimization and validation in various oncology models, including renal cell carcinoma and triple-negative breast cancer.